Analysis of the occurrence of germline mutations BRCA1\2, PALB2, CHEK2, NBN in patients with pancreatic malignancies. Single-center cohort non-randomized retrospective study
-
Published:2024-05-23
Issue:2
Volume:41
Page:33-41
-
ISSN:2687-1408
-
Container-title:Perm Medical Journal
-
language:
-
Short-container-title:Perm Medical Journal
Author:
Moiseenko V. E.12, Kardanova I. G.1, Pavlovsky A. V.1ORCID, Avanesyan G. R.1, Granov D. A.12
Affiliation:
1. Russian Research Center for Radiology and Surgical Technologies named after academician A.M. Granov 2. I.P. Pavlov First St. Petersburg Medical University
Abstract
Objective. To analyze the frequency of carriage of BRCA1\2, PALB2, CHEK2, NBN mutations in patients with malignant neoplasms of pancreas.
Materials and methods. The single-center cohort non-randomized retrospective study is based on the data of 82 patients who were examined and treated in Russian Research Center of Radiology and Surgical Technologies named after academician A.M. Granov from 2020 to 2022. Patients with confirmed ductal adenocarcinoma of pancreas were included into the study group. Screening of mutations in exons 2,10, 18, 19 of BRCA1 gene and exon 11 of BRCA2 gene was performed in these patients. In addition, oncological family histories were studied.
Results. Analysis of medical documentation data showed that 18 (22 %) patients with pancreatic cancer had a hereditary oncological history. In this cohort of patients, 5 (28 %) had relatives with pancreatic cancer, 9 (50 %) had a family history of ovarian cancer, 2 (11 %) female relatives of patients in the study group were diagnosed with breast cancer before the age of 50, also 2 (11 %) patients had a history of more than 2 relatives who suffered from breast cancer and / or prostate cancer. When evaluating the results of revealing the mutations in the entire study group (82 patients), BRCA1 (c.5266dupC) was revealed in 8 patients (9.7 %), PALB-2 (c.1592delT) – in 2 patients (2.4 %), mutations CHEK2, NBN and BRCA2 were not diagnosed in any patient. 5 (6 %) patients who were BRCA1 mutation carriers and one patient with an established PALB2 mutation, according to the analysis of case histories, had no oncological history. None of the patients in the study group was a carrier of the BRCA2, CHEK2 and NBN mutations.
Conclusions. Some patients with pancreatic cancer are carriers of germline mutations. Considering our data on the trend of association between germline mutations and pancreatic cancer, we can make an assumption about the prospect of using this indicator as one of the markers for early detection of pancreatic cancer not only in patients with hereditary risk factors for neoplasia, but also in patients without cancer anamnesis. To obtain the results, further observation of patients in the study group and randomized multicenter studies are required.
Reference21 articles.
1. Jian-Xiong Hu, Cheng-Fei Zhao, Wen-Biao Chen, Qi-Cai Liu, Qu-Wen Li, Yan-Ya Lin, and Feng Gao. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021; 27 (27): 4298–4321. 2. Моисеенко В.Е., Павловский А.В., Гранов Д.А., Кочорова Л.В., Додонова И.В., Хижа В.В., Язенок А.В., Яковенко Т.В. Анализ статистических показателей населения Санкт-Петербурга, страдающих злокачественными новообразованиями поджелудочной железы. Вестник Российской военно-медицинской академии 2021; 23 (2): 155–164 / Moiseenko V.E., Pavlovskij A.V., Granov D.A., Kochorova L.V., Dodo-nova I.V., Hizha V.V., YAzenok A.V., YAko-venko T.V. Analiz statisticheskih pokazatelej naseleniya Sankt-Peterburga, stradayushchih zlokachestvennymi novoobrazovaniyami podzheludochnoj zhelezy. Vestnik Rossijskoj Voenno-medicinskoj akademii 2021; 23 (2): 155–164 (in Russian). 3. Singhi A.D., Koay E.J., Chari S.T., Maitra A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology 2019; 156 (7): 2024–2040. 4. Hamada T., Yuan C., Yurgelun M.B., Perez K., Khalaf N., Morales-Oyarvide V., Babic A., Nowak J.A., Rubinson D.A. Giannakis M., Ng K., Kraft P., Stampfer M.J., Giovannucci E.L., Fuchs C.S., Ogino S., Wolpin B.M. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer 2019; 120 (8): 848–854. 5. Canto M.I., Almario J.A., Schulick R.D., Yeo C.J., Klein A., Blackford A., Shin E.J., Sanyal A., Yenokyan G., Lennon A.M., Kamel I.R., Fishman E.K., Wolfgang C., Weiss M., Hruban R.H., & Goggins M. (2018). Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 2018; 155 (3): 740–751.e2.
|
|